Do Not Switch from Trazodone to Quetiapine for Insomnia
You should not switch from trazodone to quetiapine (Seroquel) for the treatment of insomnia. While the American Academy of Sleep Medicine (AASM) recommends against using trazodone for insomnia 1, quetiapine is not FDA-approved for insomnia and carries significantly greater safety risks, particularly increased mortality, dementia, and falls in older adults 2.
Why This Recommendation
Guideline Position on Both Medications
The 2017 AASM Clinical Practice Guideline explicitly recommends against using trazodone for sleep onset or sleep maintenance insomnia 1. However, this does not mean quetiapine is a better alternative. Quetiapine has no FDA approval for insomnia—it is only approved for schizophrenia and bipolar disorder 3. The widespread off-label use of quetiapine for insomnia represents prescribing outside evidence-based guidelines.
Critical Safety Concerns with Quetiapine
A 2025 retrospective cohort study of 375 older adults on low-dose quetiapine compared to 1,500 on trazodone revealed alarming findings 2:
- 3.1-fold increased risk of mortality (HR 3.1,95% CI 1.2-8.1)
- 8.1-fold increased risk of dementia (HR 8.1,95% CI 4.1-15.8)
- 2.8-fold increased risk of falls (HR 2.8,95% CI 1.4-5.3)
These are not minor differences—they represent substantial increases in morbidity and mortality that directly contradict the principle of "first, do no harm."
What You Should Do Instead
Rather than switching to quetiapine, consider these evidence-based alternatives:
First-line FDA-approved options the AASM recommends 1:
- Eszopiclone (2-3 mg) for sleep onset and maintenance
- Zolpidem (10 mg) for sleep onset and maintenance
- Doxepin (3-6 mg) specifically for sleep maintenance
- Suvorexant for sleep maintenance insomnia
- Ramelteon (8 mg) for sleep onset
If continuing trazodone: Despite the AASM's recommendation against it, recent 2025-2026 evidence suggests trazodone may have a role in specific contexts 4, 5:
- A 2025 meta-analysis showed trazodone significantly improved sleep quality (SMD = -0.827) in depressive patients 4
- European expert consensus (2026) supports trazodone use in MDD patients with insomnia, anxiety, or in elderly patients 5
- If your patient has comorbid depression or anxiety, trazodone may address both conditions
Important Caveats
If you're considering this switch due to trazodone side effects:
- Trazodone causes more gastrointestinal effects (constipation, nausea, diarrhea) 6
- Quetiapine causes more sedation, somnolence, and blurred vision 4
- Neither side effect profile justifies the mortality risk of quetiapine
Drug interaction warning: One case report documented serotonin syndrome when quetiapine was added to a patient already taking trazodone and sertraline 7. If your patient is on multiple serotonergic agents, adding quetiapine creates additional risk.
Special populations:
- Elderly patients: Start FDA-approved agents at lower doses; quetiapine requires starting at 50 mg/day in elderly 3 but carries the mortality/dementia risks noted above
- Hepatic impairment: Both drugs require dose adjustment, but quetiapine's safety risks remain
The Bottom Line
Switching from trazodone to quetiapine trades one non-FDA-approved insomnia treatment for another that carries 3-fold higher mortality risk. Instead, transition to an FDA-approved hypnotic that the AASM actually recommends (eszopiclone, zolpidem, doxepin, suvorexant, or ramelteon) 1. If there are compelling reasons to continue trazodone (comorbid depression, patient already tolerating it well), that may be preferable to introducing quetiapine's substantial safety risks 2.